Abiopharma

🔍 North Run Strategic Opportunities Fund I, LP (Director)

Company: LIGHTPATH TECHNOLOGIES INC (LPTH)

Report Date: 2026-03-17

Detailed Transactions and Holdings:

• Sold 104,454 shares of Class A Common Stock at $12.01 per share (Direct)
  Date: 2026-03-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 2,916,073.00 | transaction_form_type: 4 | Footnotes: F2, F1
• Sold 16,000 shares of Class A Common Stock at $12.0 per share (Direct)
  Date: 2026-03-18 | Code: S | equity_swap_involved: 0 | shares_owned_after: 2,900,073.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: The reported securities are directly held by North Run Strategic Opportunities Fund I, LP, and may be deemed to be indirectly beneficially owned by North Run Strategic Opportunities Fund I GP, LLC as the general partner of North Run Strategic Opportunities Fund I, LP. The reported securities may also be deemed to be indirectly beneficially owned by Thomas B. Ellis and Todd B. Hammer as members of North Run Strategic Opportunities Fund I GP, LLC.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.0314 inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.